Flywheel, a medical imaging data management and analysis platform, reported record momentum in 2025, launched new products aimed at clinical trial and medical device workflows, and disclosed the close of a $27.5 million equity financing round.
The company said it recently completed an oversubscribed $25 million round led by Novalis Lifesciences and 8VC, and noted the equity raise as $27.5 million in total. Flywheel said the new capital will be used to accelerate product innovation and support growth, with an emphasis on image management for clinical trials and AI model development.
Flywheel said it has broadened its focus from supporting core lab research to serving as an enterprise imaging management platform for clinical trials, medical device development, and AI innovation, centered on large-scale imaging data aggregation, curation, and analysis. Over the past year, the company launched video viewing and annotation tools and introduced Flywheel Validated, which it said streamlines 21 CFR Part 11-compliant workflows for clinical trials to enable earlier access to imaging data with provenance, reduce costs, and improve data quality.
Flywheel also shared commercial metrics for 2025, including 43% year-over-year growth in new business and a 40% increase in committed revenue. It said annual recurring revenue from pharmaceutical and medical device customers grew 106% versus the prior year, while overall net revenue retention exceeded 110%. The company said 10 of the top 20 global pharmaceutical companies and 10 of the top 20 academic medical centers use Flywheel, and that it expanded capabilities to better serve medical device companies, research sponsors, and partner sites.
KEY QUOTE:
“Imaging data holds tremendous value and is increasingly viewed as a strategic asset. Unlocking this value requires more than just a foundational infrastructure to aggregate data. It involves integrated data management, curation, compliant workflows and AI capabilities, along with access to a connected healthcare ecosystem — all at scale. Flywheel is well-positioned to uniquely transform how companies can maximize value from their imaging assets by better informing clinical trials, accelerating AI development and enabling research and clinical teams to move faster from discovery to decision.”
Hooman Hakami, CEO and Board Chair, Flywheel
